Research
Loading latest report…
Loading research access…
Information on this site is for informational purposes only and is not investment advice. Always do your own research and consult a licensed advisor before making financial decisions. Data timestamps use US Eastern Time unless noted.
UBS
Sep 17, 2026 · BHVN
Tags: BHVN clinical-readout regulatory-catalyst biotech Kv7 obesity pipeline-risk neutral-rating
Value Score: 7.0/10
Core Conclusion: UBS reiterates Neutral on Biohaven because the stock remains caught between potentially valuable pipeline optionality and unresolved execution risk. The near-term obesity data can help if taldefgrobep shows a cleaner safety profile, but UBS sees Kv7 path clarity as the bigger stock driver, while the most meaningful upside from degrader programs is further away in 2028.
Biohaven's last year has included several pipeline setbacks or uncertainties, including MDD/BD failures, SCA rejection, and Kv7 updates. UBS stays on the sidelines with a Neutral rating and a $11 target price versus a report-date price of $13.93, implying negative forecast price appreciation. The firm's logic is not that Biohaven lacks assets; it is that the important catalysts have different timing and risk profiles.
The near-term focus is still Kv7. Biohaven's FDA partial clinical hold relates to additional non-clinical studies for a BHV-7000 metabolite seen in rodents. UBS notes that the hold does not affect RISE-3, which is fully enrolled, but it pauses RISE-2 enrollment and could delay a potential filing timeline if the program succeeds. The pending SK Biopharmaceuticals deal has been announced but not closed, adding another moving piece around the Kv7 path.
UBS expects Biohaven's Phase 2 proof-of-concept obesity trial to read out around late October, based on March enrollment completion. The primary endpoint is percent change in total body weight at 24 weeks. Management expects efficacy to be in-line to slightly below prior bimagrumab efficacy, so the more important angle may be whether taldefgrobep can show cleaner tolerability.
Chart takeaway: The benchmark bar is not trivial: bimagrumab combinations show larger body-weight and fat-mass reductions in the displayed BELIEVE dataset, while apitegromab and trevogrumab provide additional competitor reference points.
Linked conclusion: For taldefgrobep, merely showing activity may not be enough; investors will likely compare the efficacy signal against a crowded and imperfect set of anti-myostatin/activin-pathway obesity datasets.
The cleaner potential read-through is safety. UBS hig
